# Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer

> **NCT00004251** · PHASE2 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 33 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** letrozole

## Key facts

- **NCT ID:** NCT00004251
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01-19
- **Primary completion:** 2002-09-13
- **Final completion:** 2011-01-18
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004251, "Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00004251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*